New York, Jan 11, 2026, 17:56 EST — The market has closed for the day.
- Shares of CRISPR Therapeutics dropped 4.5% on Friday, underperforming the wider market gain
- Investors are eyeing the company’s Monday presentation at the J.P. Morgan healthcare meeting
- Attention centers on the Casgevy launch and any shifts in 2026 projections
CRISPR Therapeutics AG slipped 4.5% to $53.84 on Friday, putting the gene-editing stock under pressure as biotech leaders and investors gear up to converge in San Francisco this week.
U.S. markets remain closed Sunday, yet the J.P. Morgan Healthcare Conference frequently shapes the tone for the opening quarter, bringing deal rumors, pipeline updates, and occasional unexpected guidance shifts.
This year, major drug patent expirations are forcing big pharma to chase fresh assets, with the biotech ETF XBI hitting a four-year peak, the Financial Times reported. “The need to take big swings becomes more pressing,” said Jeremy Meilman, JPMorgan’s head of healthcare investment banking. Financial Times
Investors in CRISPR Therapeutics seem focused less on broad narratives and more on a single, immediate hurdle: proving Casgevy, its first marketed therapy, can gain momentum without pushing back timelines or inflating costs.
The company will present Monday at 8:15 a.m. Pacific time (11:15 a.m. ET), its investor site shows.
Traders are watching closely for clear updates on patient starts, how ready treatment centers are, and payer coverage details. They’ll also scrutinize the tone for clues on how fast revenue might ramp up this year as additional sites launch.
Casgevy is a one-time, cell-based gene therapy harnessing CRISPR/Cas9 genome editing—a technique that cuts DNA at precise locations. It earned U.S. approval in December 2023 for treating sickle cell disease, joining bluebird bio’s Lyfgenia.
The therapy is developed in partnership with Vertex Pharmaceuticals, which takes the lead on global development, manufacturing, and commercialization. Vertex and CRISPR split program costs and profits 60/40 worldwide, according to Vertex.
The distinction is key for their models: Vertex records product revenue directly, whereas CRISPR’s financial outlook hinges on profit sharing once launch expenses, manufacturing, and treatment center setup are covered.
Practical frictions can quickly derail a smooth revenue curve. These therapies demand complex logistics and specialized care, so a slow ramp-up or patchy reimbursement often hits sentiment hard, even if clinical demand is solid.
CRISPR’s pipeline also targets oncology and cardiovascular disease, but its stock moves mostly hinge on management’s updates about Casgevy adoption and the related cash burn.
Bulls face the danger of expectations outpacing reality. If Monday brings signs that the rollout remains stuck or costs refuse to drop, the stock could stay volatile.
Monday’s presentation comes next, followed by the conference’s side meetings where partnerships and deal discussions often creep into the gene-editing space.
